Reports Q3 cash, cash equivalents and short-term investments were $203.3M as of September 30 compared to $305.2M as of December 31 . Adverum expects the September 30 cash position to fund operations into 2025.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADVM:
- Adverum Biotechnologies presents end of study results from OPTIC trial
- Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
- Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
- Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
- Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference